AR084093A1 - Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica - Google Patents

Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica

Info

Publication number
AR084093A1
AR084093A1 ARP110104511A ARP110104511A AR084093A1 AR 084093 A1 AR084093 A1 AR 084093A1 AR P110104511 A ARP110104511 A AR P110104511A AR P110104511 A ARP110104511 A AR P110104511A AR 084093 A1 AR084093 A1 AR 084093A1
Authority
AR
Argentina
Prior art keywords
methods
naltrexone
buproprion
attractions
prepare
Prior art date
Application number
ARP110104511A
Other languages
English (en)
Inventor
Eduardo Dunayevich
Susan Melroy
Ron Landbloom
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084093(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of AR084093A1 publication Critical patent/AR084093A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composiciones, usos, kits y métodos para reducir el trastorno por atracones o la ingesta compulsiva de alimentos. Los métodos pueden incluir administrar una combinación efectiva de una dosificación de bupropión o una sal farmacéuticamente aceptable del mismo, y una dosificación de naltrexona o una sal farmacéuticamente aceptable de la misma. Los métodos pueden incluir identificar a un paciente que tenga sobrepeso o sea obeso y proveer una combinación efectiva de bupropión y naltrexona al paciente. Los métodos pueden incluir reducir la cantidad de eventos de atracones o ingesta compulsiva de alimentos. Los métodos pueden incluir reducir la severidad de los eventos de atracones o ingesta compulsiva de alimentos.
ARP110104511A 2010-12-03 2011-12-02 Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica AR084093A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41935410P 2010-12-03 2010-12-03

Publications (1)

Publication Number Publication Date
AR084093A1 true AR084093A1 (es) 2013-04-17

Family

ID=46172302

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104511A AR084093A1 (es) 2010-12-03 2011-12-02 Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
ARP210103652A AR124497A2 (es) 2010-12-03 2021-12-23 Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210103652A AR124497A2 (es) 2010-12-03 2021-12-23 Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica

Country Status (26)

Country Link
US (2) US20130252995A1 (es)
EP (1) EP2646011B1 (es)
JP (1) JP2014508717A (es)
KR (1) KR20140035319A (es)
CN (1) CN103298462A (es)
AR (2) AR084093A1 (es)
AU (3) AU2011336298B2 (es)
BR (1) BR112013015957B1 (es)
CA (1) CA2819003A1 (es)
CL (1) CL2013001565A1 (es)
CY (1) CY1119560T1 (es)
DK (1) DK2646011T3 (es)
ES (1) ES2647232T3 (es)
HR (1) HRP20171678T1 (es)
HU (1) HUE034641T2 (es)
IL (1) IL226483A0 (es)
LT (1) LT2646011T (es)
MX (1) MX350304B (es)
NO (1) NO2646011T3 (es)
PL (1) PL2646011T3 (es)
PT (1) PT2646011T (es)
RS (1) RS56548B1 (es)
RU (1) RU2620913C2 (es)
SI (1) SI2646011T1 (es)
TW (2) TWI536986B (es)
WO (1) WO2012075453A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197250C2 (ru) * 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
EP2316456B1 (en) * 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
GB2447949B (en) * 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2009080691A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
KR20130124333A (ko) * 2010-11-08 2013-11-13 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료

Also Published As

Publication number Publication date
NO2646011T3 (es) 2018-01-13
AU2011336298B2 (en) 2017-03-02
DK2646011T3 (da) 2017-11-20
AU2011336298A1 (en) 2013-07-11
TW201735912A (zh) 2017-10-16
LT2646011T (lt) 2017-11-10
RU2620913C2 (ru) 2017-05-30
HUE034641T2 (en) 2018-02-28
US20130252995A1 (en) 2013-09-26
US20210283126A1 (en) 2021-09-16
RU2013127420A (ru) 2015-01-10
TW201228659A (en) 2012-07-16
PT2646011T (pt) 2017-11-17
WO2012075453A1 (en) 2012-06-07
PL2646011T3 (pl) 2018-01-31
SI2646011T1 (en) 2018-01-31
CA2819003A1 (en) 2012-06-07
AU2018203921A1 (en) 2018-06-21
AU2017202793B2 (en) 2018-03-08
CL2013001565A1 (es) 2014-04-04
BR112013015957A2 (pt) 2019-10-29
IL226483A0 (en) 2013-07-31
RS56548B1 (sr) 2018-02-28
MX2013006070A (es) 2013-07-29
AU2017202793A1 (en) 2017-05-18
CY1119560T1 (el) 2018-03-07
AR124497A2 (es) 2023-04-05
HRP20171678T1 (hr) 2017-12-15
EP2646011B1 (en) 2017-08-16
EP2646011A1 (en) 2013-10-09
MX350304B (es) 2017-09-04
ES2647232T3 (es) 2017-12-20
BR112013015957B1 (pt) 2021-07-20
TWI536986B (zh) 2016-06-11
JP2014508717A (ja) 2014-04-10
CN103298462A (zh) 2013-09-11
KR20140035319A (ko) 2014-03-21
EP2646011A4 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
AR124497A2 (es) Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
EA201270041A1 (ru) Лечение рассеянного склероза лаквинимодом
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
DK1778680T3 (da) Spirocykliske cyclohexaderivater
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
ATE546133T1 (de) Orale dosierform mit trisubstituierten glycerin- verbindungen
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico

Legal Events

Date Code Title Description
FC Refusal